ARID2 and non-small cell lung carcinoma: Furthermore, our study also revealed that although a difference between any SWI/SNF mutation and WT subgroups was not apparent in terms of mPFS or mOS in TMB-low patients with NSCLC, in TMB-high patients, the mPFS or mOS of patients with ARID1A, ARID1B, or ARID2 mutations was superior to those of WT patients (8.3 vs. 3.8 months; P = 0.058; HR = 0.618; 95% CI = 0.374–1.022 for PFS; and 36 vs. 12 months; P = 0.028; HR = 0.536; 95% CI = 0.302–0.954 for OS).